Angel Broking shares spike 20% after company records highest-ever quarterly profit in Q2FY21

Company witnessed strong net addition in client base which has grown by 59 percent QoQ to 5,39,567 clients in Q2FY21.

Angel Broking shares gained 20 percent intraday on October 27 following the highest-ever quarterly profit reported in Q2FY21. But the stock is yet to cross its issue price of Rs 306 per share.

It touched an intraday high of Rs 298.50 and at 11:03 hours IST was trading 16.03 percent higher at Rs 288.50 on the BSE. It listed on bourses on October 5.

The retail broking house has reported highest every quarterly profit at Rs 74.47 crore for the quarter ended September 2020, a 47.3 percent sequential growth and the year-on-year increase was 288.3 percent.

Consolidated revenue from operations grew by 30 percent quarter-on-quarter to Rs 309.85 in Q2FY21 and the year-on-year increase was 80.4 percent.

"With the use of technology we witnessed a multi-fold addition in clients, where 1 out of every 7 incremental demat account is opened with Angel Broking, led by seamless experience digital platforms," Dinesh Thakkar, Chairman & MD said.

On the NSE, it is now the fourth largest in terms of active clients and third largest in incremental addition of active clients in H1FY21.

Company witnessed strong net addition in client base which has grown by 59 percent QoQ to 5,39,567 clients in Q2FY21.

"We continue to gain significant market share across all segments. Average Daily Turnover (ADTO) has grown by 107 percent QoQ to Rs 1,28,100 crore in Q2FY21," Vinay Agrawal, CEO said.

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...

SD Solutions

Search This Blog